As respiratory syncytial virus (RSV) season approaches, the American Lung Association is spotlighting new data that show a ...

Enanta is advancing zelicapavir to Phase III trials after CMO Dr Scott Rottinghaus said it is justified by the Phase IIb data ...

Respiratory Syncytial Virus, or RSV, is the leading cause of infant hospitalization in the U.S., sending as many as 80,000 children under the age of five to the hospital each year, according to the ...

Health experts are warning people about the 'tripledemic' threat as cases of flu, RSV and the new Covid variant Stratus are ...

New RSV vaccines are now available to help prevent serious infection in people over 60. Doctors explain the RSV vaccine side ...

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...

Enanta Pharmaceuticals said its experimental respiratory syncytial virus treatment significantly quickened recovery in a mid-stage study of adults at high risk of complications from the infection.

With the threat of a "tripledemic" looming, it's essential to be aware of the symptoms of the new Covid variant or know if ...

The UK Health Security Agency (UKHSA) has urged people with symptoms of a respiratory infection, such as Covid-19, to "avoid ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

However, the most common initial sign of the new Stratus strain is a hoarse or raspy voice. This symptom may indicate that ...